ResMed study links PAP therapy to 23% lower cardiovascular ER visit, hospitalization risk in OSA patients with hypertension

ResMed

ResMed

RMD

0.00

  • ResMed flagged 13 research abstracts for SLEEP 2026 in Baltimore, with presentations scheduled for June 15-17.
  • One study to be presented points to a smartphone-based screening approach that could broaden identification of obstructive sleep apnea.
  • Another analysis slated for presentation indicates positive airway pressure remained the most common initial therapy despite expanded GLP-1 use for OSA.
  • Separate findings to be presented link PAP therapy with fewer cardiovascular-related emergency visits or hospitalizations in patients with OSA and hypertension.
  • The readouts support a strategy centered on earlier screening and sustained device-led therapy in home-based sleep care.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.